Renaissance Group LLC Purchases 3,211 Shares of Jazz Pharmaceuticals PLC $JAZZ

Renaissance Group LLC raised its position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 6.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 52,314 shares of the specialty pharmaceutical company’s stock after purchasing an additional 3,211 shares during the period. Renaissance Group LLC owned approximately 0.09% of Jazz Pharmaceuticals worth $8,893,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of the business. Hilltop National Bank bought a new position in shares of Jazz Pharmaceuticals in the fourth quarter worth about $36,000. LRI Investments LLC bought a new position in Jazz Pharmaceuticals in the 4th quarter valued at approximately $38,000. Danske Bank A S acquired a new stake in Jazz Pharmaceuticals in the third quarter valued at approximately $40,000. Geneos Wealth Management Inc. grew its stake in shares of Jazz Pharmaceuticals by 57.6% during the first quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock worth $47,000 after buying an additional 137 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd boosted its holdings in shares of Jazz Pharmaceuticals by 1,383.3% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 356 shares of the specialty pharmaceutical company’s stock valued at $47,000 after acquiring an additional 332 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on JAZZ. Royal Bank Of Canada increased their price objective on Jazz Pharmaceuticals from $195.00 to $258.00 and gave the company an “outperform” rating in a report on Wednesday, May 6th. Piper Sandler upped their price target on shares of Jazz Pharmaceuticals from $232.00 to $301.00 and gave the company an “overweight” rating in a research report on Friday, May 22nd. Robert W. Baird set a $252.00 price target on Jazz Pharmaceuticals in a report on Wednesday, May 6th. Weiss Ratings raised Jazz Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, May 26th. Finally, Bank of America boosted their price objective on Jazz Pharmaceuticals from $281.00 to $307.00 and gave the company a “buy” rating in a research note on Wednesday. Sixteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $246.06.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, Director Rick E. Winningham sold 2,741 shares of the company’s stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $241.57, for a total transaction of $662,143.37. Following the transaction, the director owned 9,567 shares in the company, valued at approximately $2,311,100.19. This represents a 22.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Heather Ann Mcsharry sold 2,000 shares of the firm’s stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $241.00, for a total transaction of $482,000.00. Following the completion of the transaction, the director directly owned 18,449 shares in the company, valued at $4,446,209. This trade represents a 9.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 10,741 shares of company stock worth $2,287,143. Insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals Trading Up 0.2%

Shares of Jazz Pharmaceuticals stock opened at $229.63 on Thursday. The stock has a market capitalization of $14.43 billion, a PE ratio of -11,475.76, a price-to-earnings-growth ratio of 0.22 and a beta of 0.32. Jazz Pharmaceuticals PLC has a 52 week low of $105.00 and a 52 week high of $243.32. The stock has a 50 day moving average price of $215.82 and a two-hundred day moving average price of $188.13. The company has a debt-to-equity ratio of 0.95, a quick ratio of 1.85 and a current ratio of 2.04.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share for the quarter. Jazz Pharmaceuticals had a return on equity of 14.56% and a net margin of 0.66%.The company had revenue of $1.07 billion for the quarter. As a group, equities analysts anticipate that Jazz Pharmaceuticals PLC will post 21.59 earnings per share for the current fiscal year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.